Barbara Leyman

Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium.

Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium.

Limburgse Reconversie Maatschappij NV (LRM) is an independent private equity firm which was founded in 1994 by the Flemish government. Limburgse Reconversie Maatschappij NV is headquartered in Hasselt, Beglium.

Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium.